Fed’s Powell opens door to potential rate cuts at Jackson Hole
In a challenging year for biotech firms, Silence Therapeutics PLC (SLN) saw its stock tumble to a 52-week low, touching down at $3.66. According to InvestingPro analysis, the company’s current market capitalization stands at $174 million, with the stock currently trading below its Fair Value. The company, which specializes in the development of gene-silencing therapies for the treatment of serious diseases, has experienced a significant downturn, with its stock price reflecting an 83.69% decline over the past year. While investors have been cautious amid sector challenges, InvestingPro data shows the company maintains strong liquidity with a current ratio of 11.14 and more cash than debt on its balance sheet. Despite regulatory hurdles and funding challenges contributing to bearish sentiment, the company achieved 36.71% revenue growth in the last twelve months. The 52-week low marks a critical juncture for the company as it strives to advance its clinical programs and restore investor confidence. Discover 10+ additional exclusive insights and detailed analysis available on InvestingPro, including comprehensive Fair Value analysis and future growth projections.
In other recent news, Silence Therapeutics has reported a notable increase in revenue for 2024, reaching $43.3 million, up from $31.6 million in 2023. This growth is largely attributed to strategic collaborations with companies like AstraZeneca (NASDAQ:AZN) and Hanseo Pharma. The company’s cash reserves are projected to support operations into 2027, with $147.3 million in cash and equivalents as of December 2024. Meanwhile, Silence Therapeutics has decided to delay the Phase 3 trial of its drug candidate zerlasiran until a partnership is secured, a move seen as extending its cash runway.
Analysts from H.C. Wainwright have maintained a Buy rating on Silence Therapeutics with a price target of $75, citing the company’s strong financial footing and advancing RNAi pipeline. In contrast, Morgan Stanley (NYSE:MS) has adjusted its price target to $45, reflecting changes in the company’s financial model and a revised probability of success for zerlasiran. Jefferies also made a slight adjustment to their price target, now set at $30, while maintaining a Buy rating.
The company is set to focus on its second asset, divesiran, for polycythemia vera, with plans to present additional Phase 1 data in 2025. Furthermore, Silence Therapeutics plans to initiate a Phase 1 trial for SLN548, targeting complement factor B, in the second half of 2025. These developments indicate the company’s continued emphasis on advancing its therapeutic pipeline for rare diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.